Skip to main content

Table 3 Baseline demographic and clinical characteristics of CN individuals remaining stable and individuals showing progression to cognitive impairment (AIBL cohort)

From: Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology

 

Stable

Progression

p value

n

115

23

NA

Age

Years (s.d.)

72 (0.670)

72 (1.539)

0.761

Female

n (%)

61 (53%)

9 (39%)

0.407

APOE-ɛ4 +ve

n (%)

39 (34%)

13 (57%)

0.044

Brain amyloid deposition

PET SUVR (s.d.)

1.35 (0.03)

1.62 (0.08)

0.008

MRI hippocampus (right, cm3)

Mean (s.d.)

3.12 (0.03)

3.08 (0.07)

0.823

MRI hippocampus (left, cm3)

Mean (s.d.)

3.22 (0.03)

3.17 (0.06)

0.642

MRI gray matter (cm3)

Mean (s.d.)

674 (4.69)

668 (10.69)

0.633

MRI white matter (cm3)

Mean (s.d.)

436 (5.099)

441 (11.049)

0.666

MMSE

Mean (s.d.)

28.895 (0.114)

28.127 (0.248)

0.006

CDR scores

Mean (s.d.)

0.024 (0.010)

0.021 (0.022)

0.893

CDR sum of boxes

Mean (s.d.)

0.035 (0.017)

0.020 (0.037)

0.719

  1. ANCOVA models adjusted for age, sex, and APOEε4 genotype. The mean and standard deviation (s.d.) are presented in the table with false discovery rate correction set at 5%